adalimumab
NHS to save £300 million by switching to Humira biosimilars
November 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
AbbVie’s Humira receives first European OK for skin condition
August 3, 2015Sales and Marketing AbbVie, Hidradenitis suppurativa, Humira, adalimumab
The European Commission has approved AbbVie’s Humira as a treatment for moderate-to-severe hidradenitis suppurativa – a chronic condition affecting the …
AbbVie’s Humira meets endpoint in eye disease study
May 6, 2015Research and Development, Sales and Marketing AbbVie, FDA, Humira, Zydus Cadila, adalimumab, uveitis
In a Phase III trial AbbVie’s anti-inflammatory medicine Humira has been shown to significantly lower the risk of uncontrolled uveitis …
AbbVie buys Pharmacyclics in $21 billion deal
March 5, 2015Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica
AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …
Late-stage successes for Amgen and Roche
February 5, 2015Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab
Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
EMA responds to redaction concerns
November 14, 2014Sales and Marketing AbbVie, EMA, Goldacre, Humira, Rasi, adalimumab, redactions, transparency
The EMA has published a response to European Ombudsman Emily O’Reilly’s questions about some of its trial data redactions. O’Reilly’s …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
